Selective interaction of a conformationally-constrained Arg-Gly-Asp (RGD) motif with the integrin receptor αvβ3 expressed on human tumor cells

Blood Cells, Molecules and Diseases

Volumn 23, Issue 2, 1997, Pages 230-241

  Lanza, Paola ^a   Felding Habermann, Brunhilde ^b   Ruggeri, Zaverio M ^b   Zanetti, Maurizio ^a   Billetta, Rosario ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Adhesion; Antibody; Antigenized; Fibroblastoma WI 38; Integrin; Melanoma M21; Osteosarcoma KRIB; ROD; Tumor cells; v 3

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CELL SURFACE RECEPTOR; FIBRONECTIN; IMMUNOGLOBULIN HEAVY CHAIN; INTEGRIN; SCLEROPROTEIN; SYNTHETIC PEPTIDE;

ANTIGEN BINDING; ARTICLE; CELL ADHESION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; LIGAND BINDING; MELANOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; TUMOR CELL LINE;

EID: 0031214022     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1997.0140     Document Type: Article

References (57)

1. 1. Hynes R. Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69:11-25, 1992.
2. 2. Hynes R. Integrins: A family of cell surface receptors. Cell 48:549-554, 1987.
3. 3. Ruoslahti E, Pierschbacher M. New perspectives in cell adhesion: RGD and integrins. Science 238:491-497, 1987.
4. 4. Albelda S, Buck C. Integrins and other cell adhesion molecules. FASEB J 4:2868-2880, 1990.
5. 5. Davies J, Warwick J, Totty N, Philp R, Helfrich M, Horton M. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 109(4):1817-1826, 1989.
6. 6. Horton MA, Davies J. Perspectives: adhesion receptors in bone. Bone Miner Res 4(6):803-808, 1989.
7. 7. Cybulsky MI, Gimbrone MJ. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251(4995):788-791, 1991.
8. 8. Ruoslahti E, Pierschbacher M. Arg-Gly-Asp: A versatile cell recognition signal. Cell 44:517-518, 1986.
9. 9. Isberg RR, Leong JM. Multiple beta 1 chain integrins are receptors for invasin, a protein that promotes bacterial penetration into mammalian cells. Cell 60(5): 861-871, 1990.
10. 10. Bergelson JM, Shepley MP, Chan BM, Hemler ME, Finberg RW. Identification of the integrin VLA-2 as a receptor for echovirus 1 [see comments]. Science 255(5052): 1718-1720, 1992.
11. 11. Plow E, Pierschbacher M, Ruoslahti E, Marguerie G, Ginsberg M. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 82:8057-8061, 1985.
12. 12. Pytela R, Pierschbacher MD, Ruoslahti E. A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci USA 82:5766-5770, 1985.
13. 13. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 231:1559-1562, 1986.
14. 14. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26):1650-1659, 1986.
15. 15. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma [see comments]. J Natl Cancer Inst 84(24):1875-1887, 1992.
16. 16. Cheresh DA. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 84(18):6471-6475, 1987.
17. 17. Janat MF, Argraves WS, Liau G. Regulation of vascular smooth muscle cell integrin expression by transforming growth factor betal and by platelet-derived growth factor-BB. J Cell Physiol 151(3):588-595, 1992.
18. 18. Cheng YF, Kramer RH. Human micro vascular endothelial cells express integrin-related complexes that mediate adhesion to the extracellular matrix. J Cell Physiol 139(2):275-286, 1989.
19. 19. Bernard M, Myers J, Chu M-L, Ramirez F, Eikenberry E, Prockop D. Structure of a cDNA for the Proa2 chain of human type I procollagen. Comparison with chick cDNA for Proa2(I) identifies structurally conserved features of the protein and the gene. Biochemistry 22:1139-1145, 1983.
20. 20. Rixon M, Chan W-Y, Davie E, Chung D.: Characterization of a complementary deoxyribonucleic acid coding for the a chain of human fibrinogen. Biochemistry 22:3237-3244, 1983.
21. 21. Ginsberg M, Pierschbacher M, Ruoslahti E, Marguerie G, Plow E. Inhibition of fibronectin binding to platelets by proteolytic fragments and synthetic peptides which support fibroblast adhesion. J Biol Chem 260: 3931-3936, 1985.
22. 22. Gehlsen K, Dillner L, Engvall E, Ruoslahti E. The human laminin receptor is a member of the integrin family of cell adhesion receptors. Science 241:1228-1229, 1988.
23. 23. Pierschbacher M, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309:30-33, 1984.
24. 24. Gehlsen K, Argraves W, Pierschbacher M, Ruoslahti E. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides. J Cell Biol 106:925-930, 1988.
25. 25. Hayman E, Pierschbacher M, Ruoslahti E.: Detachment of cells from culture substrate by soluble fibronectin peptides. J Cell Biol 100:1948-1954, 1985.
26. 26. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 233:467-470, 1986.
27. 27. Humphries MJ, Yamada KM, Olden K. Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. J Clin Invest 81:782-790, 1988.
28. 28. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264(5158):569-571, 1994.
29. 29. Saiki I, Murata J, Iida J, et al. Antimetastatic effects of synthetic polypeptides containing repeated structures of the cell adhesive Arg-Gly-Asp (RGD) and Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences. Br J Cancer 220:722-728, 1989.
30. 30. Billetta R, Zanetti M. Ligand expression using antigenization of antibody: principle and methods. Immunomethods 1:41-51, 1992.
31. 31. Zanetti M. Antigenized antibodies. Nature 355:466-467, 1992.
32. 32. Zanetti M, Filaci G, Lee RH, et al. Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif. Embo J 12(11):4375-4384, 1993.
33. 33. Giuliano AE, Sparks FC, Morton DL. Breast cancer presenting as renal colic. Am J Surg 135(6):842-845, 1978.
34. 34. Felding HB, Habermann R, Saldivar E, Ruggeri ZM: Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J Biol Chem 271(10): 5892-5900, 1996.
35. 35. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 262(36):17703-17711, 1987.
36. 36. Rhim J, Cho H, Huebner R. Non-producer human cells induced by murine sarcoma virus. Int J Cancer 15:23-29, 1975.
37. 37. Rimoldi D, Srikantan V, Wilson VL, Bassin RH, Samid D. Increased sensitivity of nontumorigenic fibroblasts expressing ras or myc oncogenes to malignant transformation induced by 5-aza-2'-deoxycytidine. Cancer Res. 51:324-330, 1991.
38. 38. Berlin O, Samid D, Donthineni RR, Akeson W, Amiel D, Woods VJ. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res 53(20):4890-4895, 1993.
39. 39. Billetta R, Hollingdale RM, Zanetti M. Immunogenicity of an engineered internal image antibody. Proc Natl Acad. Sci USA 88:4713-4717, 1991.
40. 40. Uchida N, Smilowitz H, Tanzer ML. Monovalent ionophores inhibit secretion of procollagen and fibronectin from cultured human fibroblasts. Proc Natl Acad Sci USA 76(4):1868-1872, 1979.
41. 41. Smith JW, Cheresh DA. The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. J Biol Chem 263(35):18726-18731, 1988.
42. 42. Kyte J, Doolittle RE Simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105-132, 1982.
43. 43. Rossi F, Billetta R, Ruggeri Z, Zanetti M. Engineered idiotypes. Immunochemical analysis of antigenized antibodies expressing a conformationally constrained Arg-Gly-Asp motif. Mol Immunol 32(5):341-346,1995.
44. 44. Sollazzo M, Billetta R, Zanetti M. Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding. Protein Eng 4:215-220, 1990.
45. 45. Charo IF, Nannizzi L, Phillips DR, Hsu MA, Scarborough RM. Inhibition of fibrinogen binding to GP IIb-IIIa by a GP IIIa peptide. J Biol Chem 266(3): 1415-1421, 1991.
46. 46. Wayner EA, Orlando RA, Cheresh DA. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol 113(4):919-929, 1991.
47. 47. Phillips D, Charo I, Scarborough R. GPIIb-IIIa: The responsive integrin. Cell 65:359-362, 1991.
48. 48. Lee G, Chan W, Hurle MR, et al. Strong inhibition of fibrinogen binding to platelet receptor alpha IIb beta 3 by RGD sequences installed into a presentation scaffold. Protein Eng 6(7):745-754, 1993.
49. 49. Barbas Cd, Languino LR, Smith JW. High-affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. Proc Natl Acad Sci USA 90(21): 10003-10007, 1993.
50. 50. Main A, Harvey T, Baron M, Boyd J, Campbell I. The three-dimensional structure of the tenth type III module of fibronectin: An insight into RGD-mediated interactions. Cell 71:671-678, 1992.
51. 51. Leahy DJ, Hendrickson WA, Aukhil I, Erickson HP. Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein. Science 258:987-991, 1992.
52. 52. Adler M, Lazarus R, Dennis M, Wagner G. Solution structure of kistrin, a potent platelet aggregation inhibitor and gp IIb-IIIa antagonist. Science 253:445-448, 1991.
53. 53. Saudek V, Atkinson R, Pelton J. Three-dimensional structure of echistatin, the smallest active RGD protein. Biochemistry 30:7369-7372, 1991.
54. 54. Leahy DJ, Aukhil I, Erickson HP. 2.0 A crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 84(1):155-164, 1996.
55. 55. Krezel AM, Wagner G, Seymour UJ, Lazarus RA. Structure of the RGD protein decorsin: conserved motif and distinct function in leech proteins that affect blood clotting. Science 264(5167):1944-1947, 1994.
56. 56. Yamada T, Song H, Inaka K, Shimada Y, Kikuchi M, Matsushima M. Structure of a conformationally constrained Arg-Gly-Asp sequence inserted into human lysozyme. J Biol Chem 270(11):5687-5690, 1995.
57. 57. Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. J Biol Chem 262(36): 17294-17298, 1987.